Navigation Links
PURE Bioscience CEO to Ring NASDAQ Closing Bell
Date:7/11/2008

SAN DIEGO, July 11 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) announced today that Michael L. Krall, the company's president and CEO, is scheduled to ring the closing bell at the NASDAQ Stock Exchange at 4:00 PM on Tuesday, July 15, 2008, to commemorate PURE's return to the NASDAQ stock market on April 2, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

A live webcast of the closing ceremony will begin at 3:50 PM and can be viewed via The MarketSite Webcam by launching this link: http://www.nasdaq.com/about/marketsitetowervideo.asx.

Earlier this month, PURE entered into an agreement with FTA Therapeutics, LLC for the development and licensing of silver dihydrogen citrate (SDC)-based products for clinical projects for FDA-regulated dermatology, wound care and medical biofilm control products. In April, PURE announced a partnership with Rockline Industries Inc, for North American distribution of PURE's ready-to-use "Powered by SDC" disinfectant product and for the development and North American distribution of wipes products, as well as new disinfectant, sanitizer and preservative products containing the company's patented antimicrobial, silver dihydrogen citrate (SDC).

"Powered by SDC(TM)"

SDC, PURE Bioscience's flagship technology, is the first new disinfectant active to be registered by the EPA in more than 30 years, and "Powered by SDC" disinfectants combine extraordinary broad spectrum antimicrobial action with a previously unattainable safety profile. SDC is a patented, aqueous non-toxic antimicrobial, which is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. PURE also manufactures and sells varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third-party products.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Paul G. Henning, Vice President

Cameron Associates

212 554 5462

paul@cameronassoc.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):